Clinical Trials Browser

INDUSTRY × Breast Neoplasms × Ogivri × Clear all

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Phase 1 Suspended

Breast Neoplasms, Neoplasm Metastasis